MacroGenics, Inc.
As of Oct 22, 2026, MacroGenics is in Stage 3, the topping phase, now in week 10 (since Aug 18, 2026). It closed at $3.63, 25.3% below its 52-week high and above its 200-day average, which is rising.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MGNX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MGNX among Biotechnology62nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …62 | MGNX | Stage 3 · wk 10 | 92 | −4.5% |
MacroGenics: quick answers
What stage is MacroGenics in?
As of Oct 22, 2026, MacroGenics (MGNX) is in Stage 3, the topping phase. It entered Stage 3 on Aug 18, 2026 and is in week 10. What the four stages mean
Is MacroGenics in an uptrend?
Its uptrend has stalled. MacroGenics is in Stage 3, the topping phase that follows an advance. It trades 6.7% above its 200-day average, which is rising.
How far is MacroGenics from its 52-week high?
MacroGenics closed at $3.63 on Oct 22, 2026, 25.3% below its 52-week high of $4.86. Its 52-week low is $1.33.
How has MacroGenics performed over the past year?
As of Oct 22, 2026, MacroGenics is up 79.7% over the past year and up 125.5% so far in 2026.
Which sector and industry is MacroGenics in?
MacroGenics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.